The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Next generation of agents for lung cancer
Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses the next generation of agents for lung cancer as presented in the 20th annual Internation Lung Cancer Congress (ILCC) 2020. Prof. Herbst updates us on the use of the KRAS(G12C) inhibitor, AMG 510, in lung cancer, combination immunotherapy and the importance of identifying novel checkpoint targets including siglec-15. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
